The Effects of Different Classes of Antihypertensive Drugs on Patients with COVID-19 and Hypertension: A Mini-Review

Nozari, Farnoosh; Hamidizadeh, Nasrin

doi:10.1155/2022/5937802

Cited by 8 publications

(9 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No association was found between using other antihypertensive drugs including CCBs, beta‐blockers, and diuretics and the incidence and severity of COVID‐19. In contrast to other reviews, Nozari and Hamidizadeh investigated the effects of antihypertensive drugs on COVID‐19 only in patients with essential hypertension 17 . They suggest that ACE inhibitors and ARBs may be better choices to treat hypertension in this population.…”

Section: Discussionmentioning

confidence: 99%

“…The fact that ACE inhibitors were the drugs with the highest likelihood of being initiated to a patient infected with COVID‐19 is not surprising since according to some hypotheses, it may have some benefit compared with the other antihypertensive agents. 16 , 17 In a meta‐analysis, Ren et al concluded that the mortality and severity of COVID‐19 were significantly lower in patients taking ACE inhibitors/ARBs than in controls. 16 No association was found between using other antihypertensive drugs including CCBs, beta‐blockers, and diuretics and the incidence and severity of COVID‐19.…”

Section: Discussionmentioning

confidence: 99%

“…In contrast to other reviews, Nozari and Hamidizadeh investigated the effects of antihypertensive drugs on COVID‐19 only in patients with essential hypertension. 17 They suggest that ACE inhibitors and ARBs may be better choices to treat hypertension in this population. Conversely, diuretics can be considered the least effective drug in the setting of concomitant hypertension and COVID‐19.…”

Section: Discussionmentioning

confidence: 99%

“…Overall, the existing literature emphasizes the importance of continuing to use antihypertensive agents in patients with hypertension who develop COVID‐19 16,17 . Given the challenges maintaining treatment during the pandemic, it is important to study the prescribing and use of antihypertensives.…”

Section: Introductionmentioning

confidence: 99%

“…15 Overall, the existing literature emphasizes the importance of continuing to use antihypertensive agents in patients with hypertension who develop COVID-19. 16,17 Given the challenges maintaining treatment during the pandemic, it is important to study the prescribing and use of antihypertensives. The aim of this study was to assess initiations of different antihypertensive medicines to patients infected with COVID-19 compared with matched controls from the general population.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Initiation of antihypertensive drugs to patients with confirmed COVID‐19—A population‐based cohort study in Sweden

Mousa

Nyberg

Hajiebrahimi

et al. 2022

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Purpose Hypertension is an important risk factor for severe outcomes in patients with COVID‐19, and antihypertensive drugs may have a protective effect. However, the pandemic may have negatively impacted health care services for chronic diseases. The aim of this study was to assess initiations of antihypertensive medicines in patients infected by COVID‐19. Methods A cohort study including all Swedish residents 20–80 years old with a COVID‐19 positive test compared with an unexposed group without COVID‐19 matched for age, sex, and index date (date of confirmed COVID‐19). Data were collected within SCIFI‐PEARL, a study including linked data on COVID tests, hospital diagnoses, dispensed prescriptions, and socioeconomic data from Swedish national registers. Initiations of different antihypertensive drugs were studied from March 2020 until October 2020. Associations between COVID‐19 and initiation of antihypertensives were assessed by a multivariable Cox proportional hazards model. Results A total of 224 582 patients (exposed and unexposed) were included. After adjusting for cardiovascular comorbidities and education level, ACEi was the most commonly initiated antihypertensive agent to patients with COVID‐19. Hazard ratio and 95% confidence interval for initiation of drug therapy was 1.83 [1.53–2.19] for ACEi, followed by beta‐blockers 1.74 [1.55–1.95], calcium channel blockers 1.61 [1.41–1.83], angiotensin receptor blockers 1.61 [1.40–1.86], and diuretics 1.53 [1.32–1.77]. Conclusion All antihypertensive medicines were initiated more frequently in COVID‐19 patients. This can either be associated with hypertension caused by the COVID‐19 infection, more frequent diagnosis of hypertension among people with COVID‐19 since they consult health care, or residual confounding factors not adjusted for in the study.

show abstract

Section: Discussionmentioning

confidence: 99%